Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial-Reference-Cited by-同舟云学术

Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

Published:2015-04-27 Issue:7 Volume:17 Page:735-742
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Zannad Faiez¹,Greenberg Barry²,Cleland John G.F.³,Gheorghiade Mihai⁴,van Veldhuisen Dirk J.⁵,Mehra Mandeep R.⁶,Anker Stefan D.⁷,Byra William M.⁸,Fu Min⁸,Mills Roger M.⁸

Affiliation:

1. Inserm Centre d'Investigation Clinique CIC 1433, UMR 1116, CHU de Nancy Institut Lorrain du Coeur et des Vaisseaux Université de Lorraine Nancy France

2. Department of Medicine, Cardiology Division University of California San Diego, La Jolla CA USA

3. National Heart and Lung Institute Royal Brompton and Harefield Hospitals, Imperial College London England

4. Center for Cardiovascular Innovation Northwestern University Feinberg School of Medicine Chicago IL USA

5. Department of Cardiology, University Medical Center Groningen University of Groningen Groningen the Netherlands

6. Brigham and Women's Hospital Heart and Vascular Center, and Harvard Medical School Boston MA USA

7. Division of Innovative Clinical Trials, Department of Cardiology University Medical Centre Göttingen (UMG) Göttingen Germany

8. Janssen Research & Development LLC 920 US 202 Raritan NJ USA

Funder

Janssen Research & Development, LLC

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.266

Reference37 articles.

1. Epidemiology and risk profile of heart failure

2. The Heterogeneity of Heart Failure

3. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines;Yancy CW;Circulation,2013

4. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

5. Management of acute decompensated heart failure

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-24

2. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF;BMJ Open;2023-08

3. Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction;Scientific Reports;2022-05-20

4. Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardiopulmonary Disease;Chest;2022-05

5. Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis;Journal of Acute Disease;2022